Kymera Therapeutics (KYMR) Total Liabilities (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Total Liabilities of $129.4 million for Q1 2026, down 2.04% year-over-year from $132.1 million in Q1 2025, and down 20.7% quarter-over-quarter from $163.1 million in Q4 2025.
Kymera Therapeutics (KYMR) Total Liabilities (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Total Liabilities for 8 consecutive years, with $129.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 2.04% year-over-year to $129.4 million; the TTM figure through Mar 2026 stood at $129.4 million (down 2.04% YoY), while the FY2025 annual figure was $163.1 million, up 14.56% from the prior year.
- Total Liabilities eased to $129.4 million in Q1 2026 per KYMR's latest filing, from $163.1 million in the prior quarter.
- Across five years, Total Liabilities topped out at $180.8 million in Q4 2023 and bottomed at $113.0 million in Q4 2022.
- Historically, Total Liabilities has averaged $144.5 million across 5 years, with a median of $142.4 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities dropped 29.04% — and 2023, when it soared 60.01%.
- Kymera Therapeutics' Total Liabilities stood at $113.0 million in 2022, then jumped by 60.01% to $180.8 million in 2023, then dropped by 21.22% to $142.4 million in 2024, then advanced by 14.56% to $163.1 million in 2025, then slipped by 20.7% to $129.4 million in 2026.
- Business Quant data shows KYMR's Total Liabilities at $129.4 million in Q1 2026, $163.1 million in Q4 2025, and $155.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 136.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 136.19 Mn |
| Mar 31, 2026 | 129.38 Mn |
| Dec 31, 2025 | 163.15 Mn |
| Sep 30, 2025 | 155.79 Mn |
| Jun 30, 2025 | 159.59 Mn |
| Mar 31, 2025 | 132.08 Mn |
| Dec 31, 2024 | 142.42 Mn |
| Sep 30, 2024 | 141.91 Mn |
| Jun 30, 2024 | 141.10 Mn |
| Mar 31, 2024 | 157.05 Mn |
| Dec 31, 2023 | 180.79 Mn |
| Sep 30, 2023 | 156.84 Mn |
| Jun 30, 2023 | 146.52 Mn |
| Mar 31, 2023 | 151.90 Mn |
| Dec 31, 2022 | 112.98 Mn |
| Sep 30, 2022 | 125.59 Mn |
| Jun 30, 2022 | 125.47 Mn |
| Mar 31, 2022 | 134.34 Mn |
| Dec 31, 2021 | 146.27 Mn |
| Sep 30, 2021 | 159.32 Mn |